Bisphosphonate Bone Metastases Trials Demographic and Prognostic Variables(12, 010)

Pamidronate Study 12 ZOMETAź Study 010

Pam ZOMETA ZOMETA Pam  90 mg Placebo 4 mg 8/4 mg 90 mg Variable N = 198 N = 179 N = 183 N = 160 N = 167

Age, yr Mean ± s.d. 64.1 ± 9.4 62.7 ± 10.1 63.1 ± 10.52 62.2 ± 11.37 62.6 ± 11.41 Median 66.0 63.0 62.0 63.0 62.0

Time from initialdiagnosis to Visit 2, mo Mean ± s.d. 30.5 ± 32.2 27.7 ± 33.5 18.0 ± 32.24 13.5 ± 21.75 17.3 ± 28.62 Median 19.3 14.4 2.8 2.6 2.7

42

Previous slide

Next slide

Back to first slide

View graphic version